Hikma Pharmaceuticals PLC
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Hikma Pharmaceuticals PLC's yearly results (2022–2025), compared with companies in United Kingdom. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $48 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $47 tied up three years earlier. More money tied up than 93% of companies in United Kingdom.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 91% of companies in United Kingdom.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$169Over the last 3 years, every $100 of reported profit came with $169 of operating cash.
Higher than 55% of companies in United Kingdom.
Self-Funding Ratio
2.1×Over the last 3 years its own operating cash covered its investment spending (capex) 2.1 times.
Lower than 69% of companies in United Kingdom.
Cash Locked Ratio
$48For every $100 of sales, $48 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $47 tied up three years earlier.
More money tied up than 93% of companies in United Kingdom.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 91% of companies in United Kingdom.
Growth Efficiency Ratio
$26Sales grew 33% in 3 years; of every extra $100 of sales, $26 became extra profit.
Higher than 54% of companies in United Kingdom.
Asset Productivity Ratio
+33% / +27%In 3 years sales changed by +33% while total assets changed by +27%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
4.1×Debt due within a year is covered 4.1 times by its yearly operating cash.
Lower than 53% of companies in United Kingdom.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
79%Of every $100 the company owns, $79 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 50% of companies in United Kingdom.
Tangible Net Worth Ratio
55%Of every $100 of net worth, $55 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 55% of companies in United Kingdom.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Hikma Pharmaceuticals PLC owes $0.56 for every $1 it owns. Net profit rose 12% in the year to Dec 2025, and grew 29% a year on average over 3 years.
Compared with companies in United Kingdom · latest annual results Dec 2025.
P/E ratio
12.9Investors pay $12.9 for every $1 of Hikma Pharmaceuticals PLC's yearly profit, lower than 82% of companies in United Kingdom.
P/B ratio
1.86The share price is 1.86 times Hikma Pharmaceuticals PLC's book value per share, lower than 71% of companies in United Kingdom.
Market cap
£3.5 BThe total market value of all of Hikma Pharmaceuticals PLC's shares at today's price (share price × number of shares), smaller than 91% of companies in United Kingdom. PosiCap size class: Meso Cap.
Net worth (book value)
$2.5 BWhat Hikma Pharmaceuticals PLC would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Return on equity (ROE)
15.4%Hikma Pharmaceuticals PLC earned 15.4% on its shareholders' money over the last year, higher than 52% of companies in United Kingdom.
Owes vs Owns
0.56×Hikma Pharmaceuticals PLC owes $0.56 for every $1 it owns (moderate), lower than 61% of companies in United Kingdom.
Dividend yield
3.85%Hikma Pharmaceuticals PLC pays 3.85% of its share price as dividends a year, higher than 77% of dividend-paying companies in United Kingdom.
Revenue growth
+7%Revenue rose 7% in the year to Dec 2025, and grew 10% a year on average over 3 years.
Profit growth
+12%Net profit rose 12% in the year to Dec 2025, and grew 29% a year on average over 3 years.
Profit margin
12.0%Hikma Pharmaceuticals PLC keeps $12 of every $100 of revenue as net profit.
Cash quality
1.08×Cash from Hikma Pharmaceuticals PLC's business was 1.08× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
7.2×Hikma Pharmaceuticals PLC's operating profit covered its interest costs 7.2 times in the year to Dec 2025.
Cash vs debt
Net debtHikma Pharmaceuticals PLC had $1.4 B more debt than cash (net debt) at Dec 2025.
Questions
What is Hikma Pharmaceuticals PLC's P/E ratio?
Investors pay $12.9 for every $1 of Hikma Pharmaceuticals PLC's yearly profit, lower than 82% of companies in United Kingdom.
What is Hikma Pharmaceuticals PLC's return on equity?
Hikma Pharmaceuticals PLC earned 15.4% on its shareholders' money over the last year, higher than 52% of companies in United Kingdom.
How much does Hikma Pharmaceuticals PLC owe compared with what it owns?
Hikma Pharmaceuticals PLC owes $0.56 for every $1 it owns (moderate), lower than 61% of companies in United Kingdom.
Does Hikma Pharmaceuticals PLC pay a dividend?
Yes. Hikma Pharmaceuticals PLC pays 3.85% of its share price as dividends a year, higher than 77% of dividend-paying companies in United Kingdom.
Is Hikma Pharmaceuticals PLC's revenue growing?
Revenue rose 7% in the year to Dec 2025, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.